概要
10th DIA Cell and Gene Therapy Products Symposium in Japan
10th Anniversary Symposium - Shaping Our Future -
Healthcare continues to evolve, with advances in medical technology constantly driven by both academic exploration and the demands of society. For the past ten years, experts from industry, academia, and government have discussed the future of cell and gene therapy in Japan at this symposium from the regulatory, technology, and business perspectives. Some of these visions of the future that we have discussed have already become reality and are now evolving into the future’s next phase.
This year’s symposium will continue to provide a “forum for dialogue” to envision, through our discussions, future expansions in cell and gene therapy products and to share current issues and guidelines for the future. We are planning these five sessions to analyze the current status of cell therapy and gene therapy from various perspectives and create a vision for their future with you. By sharing our latest results and knowledge through these sessions, we hope to envision “shaping our future” together with you.
- Establishing a mature ecosystem for new modalities : Lessons learned from precedent success cases
- Ten years of history and the future : Let’s ask the past chairmans (Memorial Session)
- Human resources who will shape the future of regenerative medicine : Co-creation by expertise and bird’s eye view
- Stable manufacturing of cellular therapeutic products : Consistent manufacturing processes throughout the product life cycle
- Realizing the true value of the conditional and time-limited approval system
In addition, key opinion leaders responsible for cell therapy and gene therapy research and development programs from academia and industry, as well as government / regulatory officials, will be invited to deliver the latest information and topics through keynote lectures and other sessions.
This symposium will be held in a hybrid format. To provide a more focused location for personal dialogue, we will prepare a venue for face-to-face participation at the Nihonbashi Life Science Building along with a networking event for the free exchange of opinions. To make this symposium available to as many people as possible, participants will be able to choose to participate in person or online. Lecture materials and videos will be distributed to attendees after the symposium.
We look forward to your participation.
* Please note that there may be restrictions on recording and sharing materials based on the content and nature of each session or lecture.
Featured
Want to learn more about 10th DIA Cell and Gene Therapy Products Symposium in Japan? You've come to the right site!
プログラム委員会
-
Kiyoshi Okada, MD, PhD Professor , Deputy Director, Regenerative Medicine Support Office, Future Medica
the University of Osaka & the University of Osaka Hospital, Japan -
Yasuko Terao, PhD Head, External Scientific Engagement, R&D Japan Region,
Takeda Pharmaceutical Co., Ltd., Japan -
Hiroyuki Suda, MSc VP, Clinical Development Strategy
KORTUC Inc., Japan -
Akiyo Fujikawa Senior Director of Regulatory Affairs
Aurion Biotech Japan, LLC, Japan -
Ryutaro Hirasawa CMC Regulatory Affairs, Associate Director
Daiichi Sankyo Co., Ltd., Japan -
Akiko Ikeda, RPh PRIMO, External Researcher/Consultant
National Cancer Center, Japan -
Ikuo Kawauchi Senior Expert,International Standards Promotion Office,Intellectual Property Div
FUJIFILM Holdings Corporation, Japan -
Akihiro Kume Advisor, Corporate Planning Office
RPM Co., Ltd, Japan -
Keiji Miyamoto Principal Post-Marketing Regulatory Affairs Dep.
Daiichi Sankyo Co.,Ltd., Japan -
Sumimasa Nagai, MD, PhD Institute for Advancement of Clinical and Translational Science(iACT)
Kyoto University Hospital, Japan -
Atsushi Nishikawa Reviewer, Office of Cellular and Tissue-based Products
Pharmaceuticals and Medical Devices Agency (PMDA), Japan -
Gentaro Tajima, MS Director, Regulatory Affairs
Ultragenyx Japan K.K., Japan -
Maki Tanaka General Manager, Project Management Department
Takara Bio Inc., Japan -
Yoshie Tsurumaki
HEALIOS K.K., Japan -
Satoshi Yasuda, PhD Head, Division of Cell-Based Therapeutic Products
National Institute of Health Sciences, Japan -
Mika Yoshimatsu Head of CMC Development
T Cell Nouveau Inc., Japan -
Ayaha Kuriyama
National Cancer Center Hospital, Japan -
Futaba Nagata
PPG Service, Japan -
Hiroto Asou Reviewer, Office of New Drug IV
Pharmaceuticals and Medical Devices Agency (PMDA), Japan